title: Profuse oral secretions after propafenone administration in neonates.
abstract: Propafenone, an antiarrhythmic drug that is effective for treating supraventricular tachycardias, can induce well-known proarrhythmic and systemic adverse effects. We describe a previously unreported adverse effect in 3 newborns: oral propafenone-induced profuse oral secretions and respiratory distress of sufficient severity to necessitate discontinuation of propafenone.
authors.affiliation: Department of Neonatology, Bambino Gesù Children's Hospital, Rome, Italy. piersigilli@opbg.net
authors.forename: Fiammetta
authors.initials: F
authors.lastname: Piersigilli
authors.forename: Cinzia
authors.initials: C
authors.lastname: Auriti
authors.forename: Massimo Stefano
authors.initials: MS
authors.lastname: Silvetti
authors.forename: Gabriella
authors.initials: G
authors.lastname: Marrocco
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Drago
authors.forename: Giulio
authors.initials: G
authors.lastname: Seganti
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D012634:Bodily Secretions; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009055:Mouth; D011405:Propafenone / Q000009:adverse effects*; D012127:Respiratory Distress Syndrome, Newborn / Q000139:chemically induced*; D012720:Severity of Illness Index
chemical_list: D000889:Anti-Arrhythmia Agents; D011405:Propafenone